Drug-delivery research shows early promise
Nanotechnology drug delivery could provide breakthrough in cancer treatment
Amiji and his collaborators from the Colleges of Arts and Sciences and Engineering at the University in Boston, Massachusetts, US have been awarded R21 grants by the National Institutes of Health (NIH) to support their research. The NIH’s R21 programme encourages novel and high-risk/high-reward research by providing support for the early and conceptual stages of project development.
The National Cancer Institute has awarded a two-year, US$350,000 grant to develop more potent therapies for killing cancer cells that become resistant after initial chemotherapeutic treatment.
Amiji, working with chemistry and chemical biology professors Robert Hanson and Max Diem, will explore whether including the cell killer ceramide as a part of chemotherapy will kill tumour cells that are resistant to other treatments. Using nanocarrier technology, the combination treatment would be delivered directly to a cancer cell’s mitochondria to trigger cell death.
The National Institute of Neurological Diseases and Stroke has awarded a two-year, US$475,000 grant to Amiji and chemical engineering professor Rebecca Carrier to examine a ‘nano-emulsion’ system of delivery that will allow drugs to cross the blood-brain barrier. The process could greatly increase the recovery chances of a patient with Parkinson’s or HIV/AIDS, because ‘having a system to get these drug therapies to their appropriate place of action is critical,’ said Amiji.
Current drugs developed for treating brain diseases cannot reach the brain 98% of the time because of the low permeability of the blood-brain barrier. Researchers are investigating whether a nano-sized mixture of water, oil droplets rich in omega-3 fatty acids and curcumin, an Indian spice, will help drugs cross the blood-brain barrier by increasing its permeability.
You may also like
Trending Articles
You may also like
Pharmaceutical
ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research
ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Pharmaceutical
Asahi Kasei expands Sonanos portfolio with next-generation excipients for injectable drug formulation
Asahi Kasei has introduced two new speciality grades in its Sonanos excipient line designed to enhance sustained release and solubility in injectable drugs and plans GMP-compliant production by 2027
Research & Development
Pharma leaders must separate AI hype from actionable opportunity, warns NIRAS
A new report from the company urges pharmaceutical executives to approach AI adoption with trust, transparency and traceability, outlining how the technology can drive compliance and productivity whilst warning against risks from poor data quality and opaque models
Research & Development
UK and Japan biotech associations sign MoU to strengthen life sciences collaboration
The UK BioIndustry Association and Japan Bioindustry Association have signed a Memorandum of Understanding to connect the two nations’ biotech ecosystems, promoting joint innovation, trade and the development of new biotechnologies